euro adhoc: Intercell AG
other
US Defense Logistics Agency announces plans
to enter into supply contract to purchase Japanese Encephalitis vaccine
» Request for Proposal (RFP) aiming at exclusive, multiyear contract for
Japanese Encephalitis ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
Company Information
21.08.2008
Vienna (Austria), August 21, 2008 - Intercell AG (VSE: ICLL) announced that the Defense Logistics Agency (DLA), United States Department of Defense, has posted today a Request for Proposal (RFP) for purchase of Japanese Encephalitis (JE) vaccine. As JE is a serious and growing public health threat in Asia, the DLA intends to enter into a contract to purchase supplies of JE vaccine for use with military personnel who are deployed to affected countries.
The major details of this RFP are as follows:
» Exclusive contract to supply DLA with their requirements for JE vaccine
» Multiyear contract, with annual options to facilitate price and quantity modifications
» Duration of contract will be 5 years, at minimum
Intercell has already been in close contact with the DLA regarding this RFP and believes one reason for this proposed contract at this time is the pending Biological License Application (BLA) with the US Food and Drug Administration (FDA) for Intercell´s JE vaccine. Intercell submitted the BLA for its JE vaccine in December 2007 and anticipates FDA approval and subsequent first sales to the military markets in the next few months.
"We are pleased that the DLA has announced this RFP to establish a contract for supply of JE vaccine," stated Gerd Zettlmeissl, Chief Executive Officer of Intercell. "Intercell´s JE vaccine was developed in collaboration with the Walter Reed Army Institute (US Department of Defense) and we look forward to continuing this valued relationship by securing a long-term, exclusive contract for supply of the vaccine for use in the military´s JE immunization program. Intercell plans to respond to this RFP in a timely manner and we are optimistic that we can successfully close a contract in due time."
Japanese encephalitis, a mosquito-borne flaviviral infection, remains virulent in Asia and has recently spread to countries not previously infected. Hence, the virus is a constant health threat to millions of civilian travelers and military personnel visiting or being deployed to affected countries, including China and India. There is no treatment for JE, so vaccination is the primary countermeasure against this disease.
end of announcement euro adhoc
Further inquiry note:
Intercell AG
Lucia Malfent
Head of Communications
Tel. +43 1 20620-303
lmalfent@intercell.com
Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market